Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 444

1.

Profile and treatment of chronic coronary syndromes in European Society of Cardiology member countries: The ESC EORP CICD-LT registry.

Komajda M, Cosentino F, Ferrari R, Kerneis M, Kosmachova E, Laroche C, Maggioni AP, Rittger H, Steg PG, Szwed H, Tavazzi L, Valgimigli M, Gale CP; CICD investigators group.

Eur J Prev Cardiol. 2020 Mar 31:2047487320912491. doi: 10.1177/2047487320912491. [Epub ahead of print] No abstract available.

PMID:
32228040
2.

Covariate adjusted reanalysis of the I-Preserve trial.

Ferreira JP, Dewan P, Jhund PS, Lorenzo-Almorós A, Duarte K, Petrie MC, Carson PE, McKelvie R, Komajda M, Zile M, Zannad F, McMurray JJV.

Clin Res Cardiol. 2020 Mar 25. doi: 10.1007/s00392-020-01632-x. [Epub ahead of print]

PMID:
32215700
3.

Correction: Exome-wide association study reveals novel susceptibility genes to sporadic dilated cardiomyopathy.

Esslinger U, Garnier S, Korniat A, Proust C, Kararigas G, Müller-Nurasyid M, Empana JP, Morley MP, Perret C, Stark K, Bick AG, Prasad SK, Kriebel J, Li J, Tiret L, Strauch K, O'Regan DP, Marguiles KB, Seidman JG, Boutouyrie P, Lacolley P, Jouven X, Hengstenberg C, Komajda M, Hakonarson H, Isnard R, Arbustini E, Grallert H, Cook SA, Seidman CE, Regitz-Zagrosek V, Cappola TP, Charron P, Cambien F, Villard E.

PLoS One. 2020 Feb 14;15(2):e0229472. doi: 10.1371/journal.pone.0229472. eCollection 2020.

4.

European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure.

Seferović PM, Coats AJS, Ponikowski P, Filippatos G, Huelsmann M, Jhund PS, Polovina MM, Komajda M, Seferović J, Sari I, Cosentino F, Ambrosio G, Metra M, Piepoli M, Chioncel O, Lund LH, Thum T, De Boer RA, Mullens W, Lopatin Y, Volterrani M, Hill L, Bauersachs J, Lyon A, Petrie MC, Anker S, Rosano GMC.

Eur J Heart Fail. 2020 Feb;22(2):196-213. doi: 10.1002/ejhf.1673. Epub 2019 Dec 9.

PMID:
31816162
5.

Sex-Related Differences in Heart Failure With Preserved Ejection Fraction.

Dewan P, Rørth R, Raparelli V, Campbell RT, Shen L, Jhund PS, Petrie MC, Anand IS, Carson PE, Desai AS, Granger CB, Køber L, Komajda M, McKelvie RS, O'Meara E, Pfeffer MA, Pitt B, Solomon SD, Swedberg K, Zile MR, McMurray JJV.

Circ Heart Fail. 2019 Dec;12(12):e006539. doi: 10.1161/CIRCHEARTFAILURE.119.006539. Epub 2019 Dec 9.

PMID:
31813280
6.

Cohort profile The ESC-EORP Chronic Ischemic Cardiovascular Disease Long-Term (CICD LT) registry.

Komajda M, Cosentino F, Ferrari R, Laroche C, Maggioni A, Steg PG, Tavazzi L, Kerneis M, Valgimigli M, Gale CP; CICD investigators group .

Eur Heart J Qual Care Clin Outcomes. 2019 Oct 11. pii: qcz057. doi: 10.1093/ehjqcco/qcz057. [Epub ahead of print]

PMID:
31605146
7.

Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m.

Bouabdallaoui N, O'Meara E, Bernier V, Komajda M, Swedberg K, Tavazzi L, Borer JS, Bohm M, Ford I, Tardif JC.

ESC Heart Fail. 2019 Dec;6(6):1199-1207. doi: 10.1002/ehf2.12513. Epub 2019 Oct 8.

8.

Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction.

Tromp J, Shen L, Jhund PS, Anand IS, Carson PE, Desai AS, Granger CB, Komajda M, McKelvie RS, Pfeffer MA, Solomon SD, Køber L, Swedberg K, Zile MR, Pitt B, Lam CSP, McMurray JJV.

J Am Coll Cardiol. 2019 Aug 6;74(5):601-612. doi: 10.1016/j.jacc.2019.05.052.

PMID:
31370950
9.

Mid-regional proatrial natriuretic peptide for predicting prognosis in hypertrophic cardiomyopathy.

Bégué C, Mörner S, Brito D, Hengstenberg C, Cleland JGF, Arbustini E, Galve E, Wichter T, Richter A, Golmard JL, Bernard M, Dubourg O, Komajda M, Charron P, Isnard R.

Heart. 2020 Feb;106(3):196-202. doi: 10.1136/heartjnl-2019-314826. Epub 2019 Jul 26.

PMID:
31350276
10.

Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction.

Shen L, Rørth R, Cosmi D, Kristensen SL, Petrie MC, Cosmi F, Latini R, Køber L, Anand IS, Carson PE, Granger CB, Komajda M, McKelvie RS, Solomon SD, Staszewsky L, Swedberg K, Huynh T, Zile MR, Jhund PS, McMurray JJV.

Eur J Heart Fail. 2019 Aug;21(8):974-984. doi: 10.1002/ejhf.1535. Epub 2019 Jul 4.

11.

Global and regional echocardiographic strain to assess the early phase of hypertrophic cardiomyopathy due to sarcomeric mutations.

Baudry G, Mansencal N, Reynaud A, Richard P, Dubourg O, Komajda M, Isnard R, Réant P, Charron P.

Eur Heart J Cardiovasc Imaging. 2020 Mar 1;21(3):291-298. doi: 10.1093/ehjci/jez084.

PMID:
31056691
12.

Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction.

Shen L, Jhund PS, Docherty KF, Petrie MC, Anand IS, Carson PE, Desai AS, Granger CB, Komajda M, McKelvie RS, Pfeffer MA, Solomon SD, Swedberg K, Zile MR, McMurray JJV.

JACC Heart Fail. 2019 May;7(5):418-427. doi: 10.1016/j.jchf.2018.12.006. Epub 2019 Apr 10.

PMID:
30981744
13.

Physicians' guideline adherence is associated with long-term heart failure mortality in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry.

Komajda M, Schöpe J, Wagenpfeil S, Tavazzi L, Böhm M, Ponikowski P, Anker SD, Filippatos GS, Cowie MR; QUALIFY Investigators.

Eur J Heart Fail. 2019 Jul;21(7):921-929. doi: 10.1002/ejhf.1459. Epub 2019 Apr 1.

PMID:
30933403
14.

Mode of presentation and mortality amongst patients hospitalized with heart failure? A report from the First Euro Heart Failure Survey.

Shoaib A, Farag M, Nolan J, Rigby A, Patwala A, Rashid M, Kwok CS, Perveen R, Clark AL, Komajda M, Cleland JGF.

Clin Res Cardiol. 2019 May;108(5):510-519. doi: 10.1007/s00392-018-1380-6. Epub 2018 Oct 25.

15.

Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta-analysis.

Komajda M, Böhm M, Borer JS, Ford I, Tavazzi L, Pannaux M, Swedberg K.

Eur J Heart Fail. 2018 Sep;20(9):1315-1322. doi: 10.1002/ejhf.1234. Epub 2018 Jun 19. Review.

16.

Role of ivabradine in management of stable angina in patients with different clinical profiles.

Kaski JC, Gloekler S, Ferrari R, Fox K, Lévy BI, Komajda M, Vardas P, Camici PG.

Open Heart. 2018 Mar 9;5(1):e000725. doi: 10.1136/openhrt-2017-000725. eCollection 2018. Review.

17.

Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology.

Seferović PM, Petrie MC, Filippatos GS, Anker SD, Rosano G, Bauersachs J, Paulus WJ, Komajda M, Cosentino F, de Boer RA, Farmakis D, Doehner W, Lambrinou E, Lopatin Y, Piepoli MF, Theodorakis MJ, Wiggers H, Lekakis J, Mebazaa A, Mamas MA, Tschöpe C, Hoes AW, Seferović JP, Logue J, McDonagh T, Riley JP, Milinković I, Polovina M, van Veldhuisen DJ, Lainscak M, Maggioni AP, Ruschitzka F, McMurray JJV.

Eur J Heart Fail. 2018 May;20(5):853-872. doi: 10.1002/ejhf.1170. Epub 2018 Mar 8. Review.

18.
19.

The chronic ischaemic cardiovascular disease ESC Pilot Registry: Results of the six-month follow-up.

Komajda M, Kerneis M, Tavazzi L, Balanescu S, Cosentino F, Cremonesi A, Ferrari R, Kownator S, Szwed H, Mintale I, Olivari Z, Rittger H, Shlyakhto EV, Slapikas R, Steg PG, Valgimigli M, Van Belle E, Tsioufis K, Majda W, Laroche C, Maggioni AP; ESC–CICD Pilot Registry Investigators.

Eur J Prev Cardiol. 2018 Mar;25(4):377-387. doi: 10.1177/2047487317751955. Epub 2018 Jan 16.

PMID:
29338315
20.

Pregnancy in women with a cardiomyopathy: Outcomes and predictors from a retrospective cohort.

Billebeau G, Etienne M, Cheikh-Khelifa R, Vauthier-Brouzes D, Gandjbakhch E, Isnard R, Nizard J, Komajda M, Dommergues M, Charron P.

Arch Cardiovasc Dis. 2018 Mar;111(3):199-209. doi: 10.1016/j.acvd.2017.05.010. Epub 2017 Nov 6.

21.

Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT.

Böhm M, Komajda M, Borer JS, Ford I, Maack C, Tavazzi L, Moyne A, Swedberg K; SHIFT Investigators.

Eur J Heart Fail. 2018 Feb;20(2):373-381. doi: 10.1002/ejhf.1021. Epub 2017 Oct 12.

22.

Empagliflozin Improves Left Ventricular Diastolic Dysfunction in a Genetic Model of Type 2 Diabetes.

Hammoudi N, Jeong D, Singh R, Farhat A, Komajda M, Mayoux E, Hajjar R, Lebeche D.

Cardiovasc Drugs Ther. 2017 Jun;31(3):233-246. doi: 10.1007/s10557-017-6734-1.

23.

Heart rate and its reduction in chronic heart failure and beyond.

Nikolovska Vukadinović A, Vukadinović D, Borer J, Cowie M, Komajda M, Lainscak M, Swedberg K, Böhm M.

Eur J Heart Fail. 2017 Oct;19(10):1230-1241. doi: 10.1002/ejhf.902. Epub 2017 Jun 19. Review.

24.

Physicians' guideline adherence is associated with better prognosis in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry.

Komajda M, Cowie MR, Tavazzi L, Ponikowski P, Anker SD, Filippatos GS; QUALIFY Investigators.

Eur J Heart Fail. 2017 Nov;19(11):1414-1423. doi: 10.1002/ejhf.887. Epub 2017 Apr 30.

25.

Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial.

Komajda M, Isnard R, Cohen-Solal A, Metra M, Pieske B, Ponikowski P, Voors AA, Dominjon F, Henon-Goburdhun C, Pannaux M, Böhm M; prEserveD left ventricular ejectIon fraction chronic heart Failure with ivabradine studY (EDIFY) Investigators.

Eur J Heart Fail. 2017 Nov;19(11):1495-1503. doi: 10.1002/ejhf.876. Epub 2017 Apr 30.

26.

Pharmacological management of chronic heart failure

Komajda M.

Rev Prat. 2017 May;67(5):498-503. French.

PMID:
30512669
27.

Management of acute heart failure

Komajda M.

Rev Prat. 2017 May;67(5):508-516. French.

PMID:
30512668
28.

Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials.

Abdul-Rahim AH, Perez AC, MacIsaac RL, Jhund PS, Claggett BL, Carson PE, Komajda M, McKelvie RS, Zile MR, Swedberg K, Yusuf S, Pfeffer MA, Solomon SD, Lip GYH, Lees KR, McMurray JJV; Candesartan in Heart failure Assessment of Reduction in Mortality and Morbidity-Preserved (CHARM-Preserved) and the Irbesartan in Heart Failure with Preserved Systolic Function (I-Preserve) Steering Committees.

Eur Heart J. 2017 Mar 7;38(10):742-750. doi: 10.1093/eurheartj/ehw509. Erratum in: Eur Heart J. 2018 Apr 21;39(16):1403.

29.

Effect of intracoronary administration of AAV1/SERCA2a on ventricular remodelling in patients with advanced systolic heart failure: results from the AGENT-HF randomized phase 2 trial.

Hulot JS, Salem JE, Redheuil A, Collet JP, Varnous S, Jourdain P, Logeart D, Gandjbakhch E, Bernard C, Hatem SN, Isnard R, Cluzel P, Le Feuvre C, Leprince P, Hammoudi N, Lemoine FM, Klatzmann D, Vicaut E, Komajda M, Montalescot G, Lompré AM, Hajjar RJ; AGENT-HF Investigators.

Eur J Heart Fail. 2017 Nov;19(11):1534-1541. doi: 10.1002/ejhf.826. Epub 2017 Apr 10.

30.

Exome-wide association study reveals novel susceptibility genes to sporadic dilated cardiomyopathy.

Esslinger U, Garnier S, Korniat A, Proust C, Kararigas G, Müller-Nurasyid M, Empana JP, Morley MP, Perret C, Stark K, Bick AG, Prasad SK, Kriebel J, Li J, Tiret L, Strauch K, O'Regan DP, Marguiles KB, Seidman JG, Boutouyrie P, Lacolley P, Jouven X, Hengstenberg C, Komajda M, Hakonarson H, Isnard R, Arbustini E, Grallert H, Cook SA, Seidman CE, Regitz-Zagrosek V, Cappola TP, Charron P, Cambien F, Villard E.

PLoS One. 2017 Mar 15;12(3):e0172995. doi: 10.1371/journal.pone.0172995. eCollection 2017. Erratum in: PLoS One. 2020 Feb 14;15(2):e0229472.

31.

Comments on meta-analysis of ivabradine as adjuvant treatment for chronic heart failure by Mizzaci et al.

Swedberg K, Böhm M, Borer JS, Ford I, Komajda M, Tavazzi L.

Int J Cardiol. 2017 Jul 15;239:2. doi: 10.1016/j.ijcard.2017.01.078. Epub 2017 Jan 23. No abstract available.

PMID:
28139302
32.

Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction).

Kristensen SL, Mogensen UM, Jhund PS, Petrie MC, Preiss D, Win S, Køber L, McKelvie RS, Zile MR, Anand IS, Komajda M, Gottdiener JS, Carson PE, McMurray JJ.

Circulation. 2017 Feb 21;135(8):724-735. doi: 10.1161/CIRCULATIONAHA.116.024593. Epub 2017 Jan 4.

PMID:
28052977
33.

Liraglutide in heart failure: caution is needed.

Komajda M.

Eur J Heart Fail. 2017 Jan;19(1):78-79. doi: 10.1002/ejhf.707. No abstract available.

34.

Brain natriuretic peptide usefulness in very elderly dyspnoeic patients: the BED study.

Plichart M, Orvoën G, Jourdain P, Quinquis L, Coste J, Escande M, Friocourt P, Paillaud E, Chedhomme FX, Labourée F, Boully C, Benetos A, Domerego JJ, Komajda M, Hanon O.

Eur J Heart Fail. 2017 Apr;19(4):540-548. doi: 10.1002/ejhf.699. Epub 2016 Dec 26.

35.

Patient journey in decompensated heart failure: An analysis in departments of cardiology and geriatrics in the Greater Paris University Hospitals.

Laveau F, Hammoudi N, Berthelot E, Belmin J, Assayag P, Cohen A, Damy T, Duboc D, Dubourg O, Hagege A, Hanon O, Isnard R, Jondeau G, Labouree F, Logeart D, Mansencal N, Meune C, Pautas E, Wolmark Y, Komajda M.

Arch Cardiovasc Dis. 2017 Jan;110(1):42-50. doi: 10.1016/j.acvd.2016.05.009. Epub 2016 Dec 21.

36.

Ivabradine.

Komajda M.

Handb Exp Pharmacol. 2017;243:167-175. doi: 10.1007/164_2016_55. Review.

PMID:
27752846
37.

Financial impact of ivabradine on reducing heart failure penalties under the Hospital Readmission Reduction Program.

Kansal AR, Krotneva S, Tafazzoli A, Patel HK, Borer JS, Böhm M, Komajda M, Maya J, Tavazzi L, Ford I, Kielhorn A.

Curr Med Res Opin. 2017 Feb;33(2):185-191. doi: 10.1080/03007995.2016.1248381. Epub 2016 Oct 27.

PMID:
27733074
38.

Low level exercise echocardiography helps diagnose early stage heart failure with preserved ejection fraction: a study of echocardiography versus catheterization.

Hammoudi N, Laveau F, Helft G, Cozic N, Barthelemy O, Ceccaldi A, Petroni T, Berman E, Komajda M, Michel PL, Mallet A, Le Feuvre C, Isnard R.

Clin Res Cardiol. 2017 Mar;106(3):192-201. doi: 10.1007/s00392-016-1039-0. Epub 2016 Sep 30.

PMID:
27695989
39.

Efficacy Profile of Ivabradine in Patients with Heart Failure plus Angina Pectoris.

Borer JS, Swedberg K, Komajda M, Ford I, Tavazzi L, Böhm M, Depre C, Wu Y, Maya J, Dominjon F.

Cardiology. 2017;136(2):138-144. doi: 10.1159/000449243. Epub 2016 Sep 10.

PMID:
27614723
40.

Budget Impact of Adding Ivabradine to Standard of Care in Patients with Chronic Systolic Heart Failure in the United States.

Borer JS, Kansal AR, Dorman ED, Krotneva S, Zheng Y, Patel HK, Tavazzi L, Komajda M, Ford I, Böhm M, Kielhorn A.

J Manag Care Spec Pharm. 2016 Sep;22(9):1064-71. doi: 10.18553/jmcp.2016.22.9.1064.

41.

Prognostic Value of Insulin-Like Growth Factor-Binding Protein 7 in Patients with Heart Failure and Preserved Ejection Fraction.

Gandhi PU, Chow SL, Rector TS, Krum H, Gaggin HK, McMurray JJ, Zile MR, Komajda M, McKelvie RS, Carson PE, Januzzi JL Jr, Anand IS.

J Card Fail. 2017 Jan;23(1):20-28. doi: 10.1016/j.cardfail.2016.06.006. Epub 2016 Jun 16.

PMID:
27317843
42.

Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of SHIFT.

Komajda M, Tavazzi L, Swedberg K, Böhm M, Borer JS, Moyne A, Ford I; SHIFT Investigators.

Eur J Heart Fail. 2016 Sep;18(9):1182-9. doi: 10.1002/ejhf.582. Epub 2016 May 22.

43.

Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I-PRESERVE) trial.

Cannon JA, Shen L, Jhund PS, Anand IS, Komajda M, McKelvie RS, Zile MR, Carson PE, McMurray JJ.

Eur J Heart Fail. 2016 Aug;18(8):1021-31. doi: 10.1002/ejhf.547. Epub 2016 May 15.

44.

Geographic Differences in Patients in a Global Acute Heart Failure Clinical Trial (from the ASCEND-HF Trial).

Metra M, Mentz RJ, Hernandez AF, Heizer GM, Armstrong PW, Clausell N, Corbalan R, Costanzo MR, Dickstein K, Dunlap ME, Ezekowitz JA, Howlett JG, Komajda M, Krum H, Lombardi C, Fonarow GC, McMurray JJ, Nieminen MS, Swedberg K, Voors AA, Starling RC, Teerlink JR, O'Connor CM.

Am J Cardiol. 2016 Jun 1;117(11):1771-8. doi: 10.1016/j.amjcard.2016.03.002. Epub 2016 Mar 19.

PMID:
27108685
45.

Physicians' adherence to guideline-recommended medications in heart failure with reduced ejection fraction: data from the QUALIFY global survey.

Komajda M, Anker SD, Cowie MR, Filippatos GS, Mengelle B, Ponikowski P, Tavazzi L; QUALIFY Investigators.

Eur J Heart Fail. 2016 May;18(5):514-22. doi: 10.1002/ejhf.510. Epub 2016 Apr 20.

46.

Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT.

Böhm M, Lloyd SM, Ford I, Borer JS, Ewen S, Laufs U, Mahfoud F, Lopez-Sendon J, Ponikowski P, Tavazzi L, Swedberg K, Komajda M.

Eur J Heart Fail. 2016 Jun;18(6):672-83. doi: 10.1002/ejhf.493. Epub 2016 Mar 8.

47.

Effect of Visit-to-Visit Variation of Heart Rate and Systolic Blood Pressure on Outcomes in Chronic Systolic Heart Failure: Results From the Systolic Heart Failure Treatment With the If Inhibitor Ivabradine Trial (SHIFT) Trial.

Böhm M, Robertson M, Borer J, Ford I, Komajda M, Mahfoud F, Ewen S, Swedberg K, Tavazzi L.

J Am Heart Assoc. 2016 Feb 12;5(2). pii: e002160. doi: 10.1161/JAHA.115.002160.

48.

Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases.

Pinto YM, Elliott PM, Arbustini E, Adler Y, Anastasakis A, Böhm M, Duboc D, Gimeno J, de Groote P, Imazio M, Heymans S, Klingel K, Komajda M, Limongelli G, Linhart A, Mogensen J, Moon J, Pieper PG, Seferovic PM, Schueler S, Zamorano JL, Caforio AL, Charron P.

Eur Heart J. 2016 Jun 14;37(23):1850-8. doi: 10.1093/eurheartj/ehv727. Epub 2016 Jan 19. Review.

PMID:
26792875
49.

The year in cardiology 2015: heart failure.

Komajda M, Ruschitzka F.

Eur Heart J. 2016 Feb 1;37(5):437-41. doi: 10.1093/eurheartj/ehv720. Epub 2016 Jan 3. No abstract available.

50.

Loop diuretics, renal function and clinical outcome in patients with heart failure and reduced ejection fraction.

Damman K, Kjekshus J, Wikstrand J, Cleland JG, Komajda M, Wedel H, Waagstein F, McMurray JJ.

Eur J Heart Fail. 2016 Mar;18(3):328-36. doi: 10.1002/ejhf.462. Epub 2015 Dec 23.

Supplemental Content

Loading ...
Support Center